Buy Pt-141, 40 mg
€46.03
PT-141 (bremelanotide), 40 mg, is a synthetic cyclic heptapeptide for analytical and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to lot-specific purity, identity and salt-form verification.
Buy PT-141 (Bremelanotide), 40 mg, for Advanced Laboratory Research in Europe
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide used as a laboratory reagent in melanocortin-receptor pharmacology, peptide analytics and controlled in vitro investigations. The commonly reported structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with formula C₅₀H₆₈N₁₄O₁₀, average molecular mass approximately 1,025.2 Da and CAS Registry Number 189691-06-3. Pharma Research .eu presents this 40 mg format for qualified European laboratory teams requiring documented peptide materials.echopeptides+2
Uncompromising Purity and Analytical Characterisation
PT-141 should be specified as the cyclic peptide:
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
The structural description should identify N-terminal acetylation, norleucine substitution, D-phenylalanine and the cyclic lactam bridge. These features distinguish PT-141 from linear melanocortin fragments and other peptide analogues. Any acetate, hydrate or alternative salt form should be recorded separately because it may change the reported mass and formula.
For laboratory procurement, the suitable target is ≥99.0% purity by RP-HPLC, subject to confirmation by the actual batch-specific certificate of analysis. Commercial research listings report PT-141 purity above 99% in some lots, but the lot chromatogram and mass-spectral identity result should control acceptance.forpeptides+1
A complete CoA should include:
-
RP-HPLC purity percentage, method and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Sequence and cyclic-structure designation.
-
Confirmation of N-acetylation, norleucine and D-Phe.
-
Free-peptide, acetate or hydrate-form information.
-
Molecular formula and molecular-mass assignment.
-
Visual appearance of the lyophilised material.
-
Residual-solvent results from synthesis and purification.
-
Water or residual-moisture content, where measured.
-
Heavy-metal or elemental-impurity results where included in the quality programme.
-
Lot number, manufacture date, retest date and storage requirements.
The commonly reported formula is C₅₀H₆₈N₁₄O₁₀, with average molecular mass approximately 1,025.16–1,025.2 g/mol and exact mass approximately 1,024.5243 Da. CAS Registry Number 189691-06-3 and PubChem CID 9941379 are widely associated with bremelanotide.pubchem.ncbi.nlm.nih+2
PT-141 is generally supplied as a white to off-white lyophilised powder. Visual inspection can identify gross discolouration, vial damage or visible contamination, but cannot establish identity or purity. Analytical release should combine appearance assessment with RP-HPLC and mass-spectral confirmation.
High purity is important because incorrect stereochemistry, incomplete cyclisation, unmodified or partially modified peptide, oxidation products and residual synthesis materials can change receptor-assay response, chromatographic retention and ionisation behaviour. A non-characterised peptide may be unsuitable for quantitative LC-MS, concentration–response studies or inter-laboratory comparison.
Principal Laboratory Applications and Research Methodologies
PT-141 is suitable for controlled laboratory research involving cyclic-peptide chemistry, melanocortin-receptor pharmacology and in vitro assay development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
Cyclic-peptide identity and impurity profiling. PT-141 can support LC-MS and RP-HPLC method development for intact-mass confirmation, retention-time assignment and detection of incomplete cyclisation or related peptide impurities.
Receptor-binding and signalling models. A verified batch may be incorporated into controlled receptor-binding, reporter-gene or second-messenger assays involving melanocortin receptor systems. Studies should include vehicle controls, receptor-negative controls where relevant, concentration verification and independent confirmation of peptide integrity.
Analytical method validation. Laboratories may evaluate precursor-ion selection, product-ion transitions, matrix effects, recovery and chromatographic separation. Cyclic structure and non-standard residues should be included in the method-development rationale.
Stability and formulation studies. Researchers may investigate temperature, light, pH, oxidation, freeze–thaw stress and container interactions. Stability-indicating methods should distinguish chemical degradation from adsorption, precipitation or sample-preparation loss.
The 40 mg quantity corresponds to approximately 39.0 µmol using the reported molecular mass of 1,025.2 g/mol. No final concentration should be stated because the reconstitution volume, solvent and exact salt form were not specified. Actual molar quantity depends on measured net content, purity, hydration and counter-ion contribution.
If bacteriostatic water or another diluent is supplied separately, its preservative and excipient profile should be assessed for compatibility with LC-MS and in vitro workflows. Solvent blanks, matrix controls and cell-compatibility testing may be required.
Compound Stability, Optimal Storage, and Safe Handling Protocols
PT-141 should remain sealed in its lyophilised state until required for a validated laboratory procedure. Research-product guidance commonly recommends low-temperature storage of the dry peptide, protected from light and moisture, with prepared solutions handled under separately validated conditions.echopeptides+1
Recommended controls include:
-
Store unopened lyophilised PT-141 at approximately −20°C unless the CoA specifies otherwise.
-
Consider −80°C for extended archival storage where supported by the stability programme.
-
Keep the container tightly closed, dry and protected from direct light.
-
Allow a sealed vial to reach room temperature before opening to minimise condensation.
-
Use low-binding tubes where adsorption could affect recovery.
-
Prepare aliquots if repeated access is expected.
-
Store short-term aqueous solutions at 2–8°C only where validated.
-
Use frozen aliquots for longer-term solution storage where supported by stability data.
-
Avoid repeated freeze–thaw cycles.
-
Record solvent, concentration, preparation date, operator and storage history.
The cyclic structure may alter proteolytic and physical stability compared with a linear peptide, but it does not eliminate risks from oxidation, adsorption, pH changes or concentration loss. A clear solution should not be assumed to retain full molecular integrity without HPLC or LC-MS confirmation.
Reconstitution should be performed using a validated laboratory procedure. Add the selected solvent gradually, allow the powder to hydrate and mix gently. Avoid vigorous agitation unless it has been shown to preserve recovery and integrity. If precipitation, persistent turbidity or unexpected colour change occurs, investigate the solution before use.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | PT-141 (bremelanotide), 40 mg |
| Common designation | Bremelanotide; PT-141 |
| Structure | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Residue count | Cyclic heptapeptide |
| IUPAC name | Full systematic name should be confirmed on the CoA; structural sequence notation is preferred for procurement |
| CAS Registry Number | 189691-06-3 |
| Molecular formula | C₅₀H₆₈N₁₄O₁₀ |
| Average molecular mass | Approximately 1,025.16–1,025.2 g/mol |
| Exact mass | Approximately 1,024.5243 Da |
| Physical state and colour | Lyophilised white to off-white powder |
| Solubility profile | Aqueous reconstitution may be feasible; solvent and buffer compatibility require assay-specific validation |
| Typical purity | Proposed target ≥99.0% by RP-HPLC; verify the actual lot-specific result |
| Identity testing | LC-MS, ESI-MS or high-resolution MS |
| Long-term storage | Typically −20°C, sealed and protected from light and moisture |
The formula, molecular mass, CAS number and cyclic structure are supported by public chemistry and research references. If the supplied product is an acetate or hydrated form, the technical table must be updated to match its CoA.pubchem.ncbi.nlm.nih+3
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position PT-141 as a documented European laboratory reagent for analytical chemists, biochemists and laboratory managers requiring a defined cyclic peptide. The product file should include a batch-specific CoA, SDS, sequence and stereochemical designation, purity result, identity data, salt-form information and storage instructions.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
PT-141’s cyclic structure and lactam bridge.
-
N-terminal acetylation, norleucine and D-Phe configuration.
-
Free-peptide versus acetate or hydrate form.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Packaging configuration and container-closure integrity.
-
Solvent compatibility and storage requirements.
-
Transport and documentation across the EU.
Pharma Research .eu should therefore be described as a potential European source for research-grade PT-141, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.